medline.ch Onkologie Urologische Tumoren

	Obesogens in Prostate Cancer: An Endocrine and Metabolic Threat. Curr Obes Rep Feijó M, Fonseca LRS, Kiss-Toth E, Socorro S, Correia S. PMID: 41739363 [PubMed - in process]
	Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy. Cancer Immunol Immunother Ciccarese C, Occhipinti D, Arduini D, Di Leo D, Neri A, Roca L, Messina G, Troisi P, Pedone RR, Fucile MA, Belletto R, Sardaro V, Ligato C, Ajdhoni R, Caliciotti F, Sighinolfi C, Tagliaferri L, Rocco B, Tortora G, Iacovelli R. PMID: 41739194 [PubMed - indexed for MEDLINE]
	A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium. Cancer Immunol Immunother Yanagisawa T, Mori K, Kawada T, Katayama S, Tsujino T, Maenosono R, Toyoda S, Nukaya T, Morinaka H, Tamura K, Fukuokaya W, Urabe F, Murakami M, Bekku K, Takahara K, Fujita K, Azuma H, Araki M, Inamoto T, Komura K, Kimura T, JK-FOOT study group. PMID: 41739193 [PubMed - indexed for MEDLINE]
	Bench-to-Bedside Evaluation of Sulforaphane/BroccoMaxÂ® on Fatty Acid Synthesis in Prostate Cancer. Cancer Prev Res (Phila) Hahm ER, Jacobs BL, Singh KB, Kim SH, Parikh R, Normolle DP, Dhir R, Oyebamiji T, Sun X, Liu Y, Appleman LJ, Gelhaus SL, Singh SV. PMID: 41738426 [PubMed - as supplied by publisher]
	Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer. J Natl Cancer Cent Huang F, Li K, Shevach JW, Wang Q. PMID: 41738039 [PubMed]
	Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer. J Natl Cancer Cent Keo V, Lu X, Zhao JC, Yu J. PMID: 41738035 [PubMed]
	Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance. J Natl Cancer Cent Gao S, Patten ND, Cai C. PMID: 41738032 [PubMed]
	Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer. J Natl Cancer Cent Shuai Y, Huang H. PMID: 41738031 [PubMed]
	Obesity-linked genes may promote prostate cancer among Asian and Hispanic immigrants to North America. Front Public Health Mercola D. PMID: 41737617 [PubMed - indexed for MEDLINE]
	The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies. Front Immunol Tratnjek L, Janev A, Kuret T, Jerman UD. PMID: 41737225 [PubMed - indexed for MEDLINE]
	Multilevel associations between prostate cancer testing and socioeconomic position: a population-based register study from Stockholm, Sweden. BMJ Public Health Rai B, Rado M, Oberg AS, Kuja-Halkola R, Clements MS. PMID: 41736807 [PubMed]
	A Case of Prostatic Mixed Germ Cell Tumor Showing Pagetoid Spread Into the Vas Deference in a Patient With Klinefelter Syndrome. Pathol Int Noto Y, Satou A, Kawano T, Fukuyama R, Miyai K, Tsuzuki T, Yanagida E. PMID: 41736172 [PubMed - indexed for MEDLINE]
	Enhancing prostate cancer diagnosis: a machine learning-based biomarker approach. Hum Genomics Porras-Quesada P, Ramírez-Mena A, Arenas-Rodríguez V, Vázquez-Alonso F, Alcalá-Fdez J, Álvarez-González B, Martínez-González LJ, Álvarez-Cubero MJ. PMID: 41736161 [PubMed - as supplied by publisher]
	Ferroptosis-autophagy crosstalk in bladder cancer: mechanisms and therapeutic implications. Mol Cancer Wang Y, Wu N, Zhang S. PMID: 41736076 [PubMed - as supplied by publisher]
	Global, regional, and national burden of early-onset prostate cancer, 1990-2021: a systematic analysis for the global burden of disease study 2021. World J Surg Oncol Ma Y, Liu Y, Liu Y, Li J, Wu B, Yu W, Yang C. PMID: 41736007 [PubMed - as supplied by publisher]
	Physical Activity, Trust, and Research Participation Among Men From Minority Ethnic Backgrounds Living With Prostate Cancer: A Qualitative Study. Psychooncology Carr J, Faghy MA, Broom D, Roscoe C, Williams K, Ashton REM. PMID: 41735200 [PubMed - indexed for MEDLINE]
	Re: Active Monitoring, Surgery, and Radiotherapy for Cribriform-positive and Cribriform-negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial. Eur Urol Bratt O, Egevad L. PMID: 41735149 [PubMed - as supplied by publisher]
	The path forward for T cell engagers in patients with prostate cancer. J Immunother Cancer Subudhi SK, Siddiqui BA, Zarrabi KK, Kelly WK, Drake CG. PMID: 41734994 [PubMed - indexed for MEDLINE]
	Histone lactatation-related genes GPR19 and SLC22A16 are important diagnostic markers and drug treatment targets for prostate cancer. Genes Genomics Yan Y, Li Z, Ye M, Li J. PMID: 41733804 [PubMed - as supplied by publisher]
	Comparative Efficacy and Toxicity of Gemcitabine-Cisplatin vs. Gemcitabine-Carboplatin in Metastatic Carcinoma of the Urinary Bladder: A Retrospective Review. Gulf J Oncolog Goel V, Jain A, Basu D, Patnaik N, Talwar V, Swamy S, Rawal S. PMID: 41733168 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 176282

Seite 1 von 8815

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung